Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

By Georgina V. Long, U. Trefzer, M. Davies, R. Kefford, P. Ascierto, P. Chapman, I. Puzanov, A. Hauschild, C. Robert, A. Algazi and 12 more. The Lancet Oncology, 2012

876 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/20ea5f0ea937a33274dc231dbab16d849a444542

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Flaherty
2. Georgina V. Long

Citations in the corpus

• Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, methodology): “as well as stratification and analysis, are often based on the presence/absence of CNS disease.(6-20,73,74) Therefore, this additional level of granularity in the M category “maps” bet-”
• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Kinase inhibitors [46] and ipilimumab and/or anti-PD1 antibody therapy [47] can be safely used even in patients with symptomatic brain metastases, in fact it has shown significant efficacy in this area [48].”